anthem biosciences limited IPO
IPO Overview
Anthem biosciences limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹— crores. The IPO price band is set at ₹570 per share, and retail investors can apply with a minimum investment of ₹14.8K as per IPO guidelines.
The Anthem biosciences limited IPO opens on 14 Jul 2025 and closes on 16 Jul 2025. The IPO allotment is expected to be finalized on 17 Jul 2025, and the equity shares are proposed to be listed on BSE, NSE on 21 Jul 2025.
Investors can refer to the Anthem biosciences limited IPO RHP-DRHP for detailed information. The issue is managed by Jm Financial Limited,Citigroup Global Markets India Private Limited,J.P. Morgan India Private Limited,Nomura Financial Advisory And Securities (India) Pvt Ltd as the book running lead manager, while Kfin Technologies Limited is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About Company
The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.
The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.
As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.
As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.
As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.
Competitive Strength
One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.
Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
Long-standing relationships with a large, diversified and loyal customer base.
Professional and experienced leadership team supported by a qualified scientific talent pool.